Endava plc ADR (DAVA)’s stock price range in the last year

While Endava plc ADR has overperformed by 6.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DAVA fell by -52.23%, with highs and lows ranging from $34.94 to $13.39, whereas the simple moving average fell by -40.05% in the last 200 days.

On May 19, 2025, JP Morgan Downgraded Endava plc ADR (NYSE: DAVA) to Neutral. A report published by TD Cowen on May 15, 2025, Downgraded its rating to ‘Hold’ for DAVA. BofA Securities also rated DAVA shares as ‘Neutral’, setting a target price of $29 on the company’s shares in an initiating report dated November 22, 2024. Redburn Atlantic Initiated an Neutral rating on May 24, 2024, and assigned a price target of $33.10. HSBC Securities May 01, 2024d its ‘Hold’ rating to ‘Buy’ for DAVA, as published in its report on May 01, 2024. JP Morgan’s report from March 19, 2024 suggests a price prediction of $49 for DAVA shares, giving the stock a ‘Overweight’ rating. Guggenheim also rated the stock as ‘Buy’.

Analysis of Endava plc ADR (DAVA)

Further, the quarter-over-quarter increase in sales is 10.98%, showing a positive trend in the upcoming months.

In order to gain a clear picture of Endava plc ADR’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of 2.85% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.88, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

An average volume of 864.72K can be a very valuable indicator of volatility for DAVA stock. On a monthly basis, the volatility of the stock is set at 3.66%, whereas on a weekly basis, it is put at 4.86%, with a loss of -5.57% over the past seven days. Furthermore, long-term investors anticipate a median target price of $23.18, showing growth from the present price of $14.76, which can serve as yet another indication of whether DAVA is worth investing in or should be passed over.

How Do You Analyze Endava plc ADR Shares?

The United Kingdom based company Endava plc ADR (DAVA) is one of the biggest names in Software – Infrastructure. When comparing Endava plc ADR shares with other companies under Technology, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 38.00, there is a growth in quarterly earnings of 715.12%.

In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.00%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 80.98% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

DAVA shares are owned by institutional investors to the tune of 80.98% at present.

Hot this week

Is Icecure Medical Ltd (NASDAQ:ICCM) stock a better investment at this time?

Currently, Icecure Medical Ltd's (ICCM) stock is trading at...

A review of ZVSA’s current quarter earnings predictions

In the current trading session, ZyVersa Therapeutics Inc's (ZVSA)...

LX’s current quarter earnings: What analysts forecast?

LexinFintech Holdings Ltd ADR (LX)'s stock is trading at...

A closer look at Humacyte Inc’s (HUMA) current quarter earnings projections

Humacyte Inc (HUMA)'s stock has witnessed a price declined...

Will Precision Biosciences Inc (DTIL) beat or miss earnings estimates this quarter?

Currently, Precision Biosciences Inc's (DTIL) stock is trading at...

Topics

Is Icecure Medical Ltd (NASDAQ:ICCM) stock a better investment at this time?

Currently, Icecure Medical Ltd's (ICCM) stock is trading at...

A review of ZVSA’s current quarter earnings predictions

In the current trading session, ZyVersa Therapeutics Inc's (ZVSA)...

LX’s current quarter earnings: What analysts forecast?

LexinFintech Holdings Ltd ADR (LX)'s stock is trading at...

A closer look at Humacyte Inc’s (HUMA) current quarter earnings projections

Humacyte Inc (HUMA)'s stock has witnessed a price declined...

Will Precision Biosciences Inc (DTIL) beat or miss earnings estimates this quarter?

Currently, Precision Biosciences Inc's (DTIL) stock is trading at...

TRIB’s earnings estimates: Are they on track to meet expectations?

In the current trading session, Trinity Biotech Plc ADR's...

What to expect from CZR’s earnings report this quarter?

Caesars Entertainment Inc (CZR)'s stock is trading at $29.1...

Predicting XPeng Inc ADR’s (XPEV) earnings for the current quarter

XPeng Inc ADR (XPEV)'s stock has witnessed a price...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.